Immix Biopharma, Inc. (IMMX)

Immix Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	225.49	93.93	17.68	17.51	13.44	17.64
Short-Term Investments	6.62	6.48	-	-	-	-
Cash & Short-Term Investments	232.11	100.41	17.68	17.51	13.44	17.64
Cash Growth	1894.40%	467.86%	0.98%	30.31%	-23.85%	4411.66%
Other Receivables	-	-	1.97	1.17	0.26	0.03
Receivables	-	-	1.97	1.17	0.26	0.03
Prepaid Expenses	1.4	0.68	0.51	1.06	1.13	0.52
Other Current Assets	0.28	0.15	0.03	0.04	0.08	-
Total Current Assets	233.79	101.24	20.2	19.79	14.9	18.19
Property, Plant & Equipment	3.25	3.49	2.73	0.05	0	0.01
Long-Term Deferred Charges	-	0.09	-	0.09	0.01	-
Other Long-Term Assets	0.02	0.02	0.02	-	-	-
Total Assets	239.11	104.84	22.95	19.93	14.91	18.19

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	5.28	5.44	5.39	1.43	0.14	0.14
Accrued Expenses	3.91	4.53	3.23	2.29	1.13	0.01
Short-Term Debt	-	-	-	-	-	0.05
Current Portion of Leases	0.11	0.14	0.07	-	-	-
Total Current Liabilities	9.3	10.11	8.69	3.72	1.27	0.2
Long-Term Leases	0.89	0.93	1.01	-	-	-
Other Long-Term Liabilities	-	-	-	-	0.48	-
Total Liabilities	10.19	11.04	9.7	3.72	1.75	0.2

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0	0	0	0
Additional Paid-In Capital	355	198.29	88.37	69.78	51.16	47.62
Retained Earnings	-126.11	-104.46	-75.02	-53.41	-37.99	-29.76
Treasury Stock	-0.1	-0.1	-0.1	-0.1	-0.1	-
Comprehensive Income & Other	0.12	0.06	-0	0.13	0.09	0.13
Total Common Equity	228.92	93.8	13.25	16.41	13.16	17.99
Minority Interest	-	-	-	-0.2	-	-
Shareholders' Equity	228.92	93.8	13.25	16.2	13.16	17.99
Total Liabilities & Equity	239.11	104.84	22.95	19.93	14.91	18.19

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	1	1.07	1.07	-	-	0.05
Net Cash (Debt)	231.11	99.34	16.61	17.51	13.44	17.59
Net Cash Growth	2081.24%	498.15%	-5.16%	30.31%	-23.63%	-
Net Cash Per Share	4.83	3.01	0.59	1.01	0.97	4.79
Filing Date Shares Outstanding	71.54	52.96	27.72	26.4	13.9	13.86
Total Common Shares Outstanding	71.54	52.95	27.54	19.92	13.89	13.23
Working Capital	224.49	91.13	11.51	16.07	13.62	17.98
Book Value Per Share	3.20	1.77	0.48	0.82	0.95	1.36
Tangible Book Value	228.92	93.8	13.25	16.41	13.16	17.99
Tangible Book Value Per Share	3.20	1.77	0.48	0.82	0.95	1.36
Machinery	1.59	1.57	0.85	0.06	-	-
Construction In Progress	-	-	0.94	-	-	-
Leasehold Improvements	1.24	1.24	-	-	-	-

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Aug 7, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 2, 2026

Data Sources Report a data error